reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
Recruiting · NCT05958017 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Miami
View the official record on ClinicalTrials.gov →Interventions studied
Standard of carereSET
What this trial is about
The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.
Who can take part
Age range
18 Years to 90 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Assigned male sex at birth and has not undergone any transgender hormonal treatment
- Reports having had sex with a male in the past 12 months
- Age 18 or older
- Is affiliated with a study referral source (e.g., AHF clinic, registry, other healthcare program or clinic) or resides in a city or county where a participating healthcare center or health program is located
- Screens positive for mild, moderate or severe stimulant use disorder in the last 12 months using the MINI
- Reports that he is not currently in drug treatment
- Is living with HIV
- Reports having an active antiretroviral prescription
- Have access to a smartphone or tablet with stable internet at least twice a week and can download applications to the smartphone or tablet
- Able to understand English
- Consents to participation in the study
- Provides sufficient locator information
- Identifies as non-Hispanic White, non-Hispanic Black/African American or Latinx/Hispanic
- Has been in stable housing for the past 3 months and intends to remain housed for the next 15 months
Exclusion criteria
- Patient appears to have diminished capacity to consent either because of cognitive impairment or severe psychiatric symptoms (e.g., mania, psychosis).
- Persons that meet criteria for prisoner status will be excluded at baseline.
- Patients who screen positive for moderate to severe opioid use disorder will be excluded from the study because effective pharmacological agents exist for the treatment of this disorder. These patients will be referred to community-based programs that provide specialized treatment for this disorder.
- Participants will be excluded prior to randomization, if they do not complete at baseline the Time-Line Follow-Back or the laboratory visit.
Where it is running
1 location listed across 1 US state.
- University of Miami - Miami, Florida, United States